Editas Medicine Announces Clinical Data Demonstrating Proof of Concept of EDIT-101 from Phase 1/2 BRILLIANCE Trial

November 17, 2022

https://www.globenewswire.com/news-release/2022/11/17/2558050/0/en/Editas-Medicine-Announces-Clinical-Data-Demonstrating-Proof-of-Concept-of-EDIT-101-from-Phase-1-2-BRILLIANCE-Trial.html

EDIT-101 demonstrates a favorable safety profile across all dose cohorts

Preliminary efficacy signals of consistent improvement in BCVA plus additional efficacy endpoints seen in homozygous patients

Read more at globenewswire.com

Related news for (EDIT)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.